soul trial oral semaglutide cardiovascular outcomes 2024 nejm 2025 results The (Semaglutide Trial) was a randomized ADA 2025: Oral Semaglutide Demonstrates – Michael Albert, MD on X:

PMID: 34934897 Konijeti, G.G., et al

Other findings from this study show that semaglutide reduces binge drinking in a dose-dependent manner, meaning higher doses of semaglutide lead to greater reductions in binge alcohol intake

It can also upregulate Bax and downregulate Bcl-2 to inhibit the progression of the cell cycle from the G1 phase to the S phase, causing tumor cells to stay in the G1 phase and increasing DNA vulnerability to damage (166)

The solution is likely to address the hormone deficiency, not stop your successful weight loss regimen

The metabolic benefits are reported in a few days post-bariatric surgery, which suggest a weight-independent effect [70]

Symptoms include chronic headaches, pulsatile tinnitus